{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are adverse events (AEs) which will occur up to 2 years that were absent before treatment or that worsened relative to pre-treatment state.","groups":[{"description":"Participants in Safety Run-in cohort received daratumumab 16 mg/kg IV once every week (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards) and JNJ-63723283 240 mg IV during Week 1 on Cycle 1 Day 2, Cycle 1 Day 15, then every 2 weeks thereafter. Each treatment cycle consisted of 28 days. Participants continued to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria were met.","id":"OG000","title":"Part 1: Daratumumab + JNJ-63723283"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set included all participants who have received at least 1 dose of study agent (JNJ-63723283 or daratumumab, partial or complete) in safety run-in phase of the study.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Number of Participants With Treatment Emergent Adverse Events (TEAE) in Safety run-in Phase (Part 1)","type":"PRIMARY","unitOfMeasure":"Participants"}